✦ LIBER ✦

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

✍ Scribed by Kevan C. Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A. Bluestone

Book ID: 113541283
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 449 KB
Volume: 132
Category: Article
ISSN: 1090-2341
DOI: 10.1016/j.clim.2009.04.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Teplizumab (Anti-CD3 mAb) Treatment Pres

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

✍ Herold, K. C.; Gitelman, S. E.; Ehlers, M. R.; Gottlieb, P. A.; Greenbaum, C. J. 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 932 KB